Shannon Rahimi

Shannon Rahimi asked about key milestones for the partnered programs PARAISO (prasinezumab) and CLEOPATRA (coramitug) in 2026 and 2027, given their primary completion dates are not expected until 2029, and what these milestones might be contingent on.

Answer

Gene Kinney, President and CEO of Prothena, highlighted upcoming scientific presentations on the TDP-43 CYTOPE program in 2026, expected data from Bristol Myers Squibb's phase II TargetTau-1 trial in the first half of 2027, and the phase III readouts for coramitug and prasinezumab in 2029. Tran Nguyen, Chief Strategy Officer and CFO, added that Prothena expects to institute a share redemption program in 2026 and has the potential to earn up to $105 million in clinical milestones from coramitug and PRX-019 in the same year.